Krilogy Financial LLC Makes New Investment in Guardant Health, Inc. $GH

Krilogy Financial LLC purchased a new position in Guardant Health, Inc. (NASDAQ:GH) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 32,436 shares of the company’s stock, valued at approximately $2,780,000.

A number of other hedge funds also recently modified their holdings of the business. Allworth Financial LP grew its position in shares of Guardant Health by 19.5% in the 3rd quarter. Allworth Financial LP now owns 844 shares of the company’s stock valued at $53,000 after purchasing an additional 138 shares during the period. Eastern Bank raised its holdings in Guardant Health by 6.9% during the 4th quarter. Eastern Bank now owns 2,160 shares of the company’s stock worth $221,000 after buying an additional 139 shares during the period. Xponance LLC lifted its stake in Guardant Health by 2.1% in the fourth quarter. Xponance LLC now owns 9,630 shares of the company’s stock valued at $984,000 after buying an additional 199 shares in the last quarter. Danske Bank A S lifted its stake in Guardant Health by 20.0% in the fourth quarter. Danske Bank A S now owns 1,200 shares of the company’s stock valued at $123,000 after buying an additional 200 shares in the last quarter. Finally, Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna boosted its holdings in shares of Guardant Health by 1.9% in the fourth quarter. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna now owns 11,000 shares of the company’s stock valued at $1,124,000 after buying an additional 200 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Price Performance

Shares of GH stock opened at $136.96 on Thursday. The stock has a market cap of $18.16 billion, a P/E ratio of -40.40 and a beta of 1.61. The company has a fifty day moving average price of $110.21 and a two-hundred day moving average price of $103.42. Guardant Health, Inc. has a one year low of $40.35 and a one year high of $141.07.

Insider Activity at Guardant Health

In related news, Director Meghan V. Joyce sold 10,000 shares of Guardant Health stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $126.98, for a total transaction of $1,269,800.00. Following the completion of the transaction, the director owned 11,183 shares in the company, valued at approximately $1,420,017.34. This trade represents a 47.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Chris Freeman sold 24,406 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $118.67, for a total value of $2,896,260.02. Following the transaction, the insider directly owned 60,034 shares in the company, valued at approximately $7,124,234.78. This trade represents a 28.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 452,513 shares of company stock worth $51,608,916 over the last ninety days. Company insiders own 5.60% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on GH shares. Royal Bank Of Canada assumed coverage on shares of Guardant Health in a report on Thursday, June 11th. They set an “outperform” rating and a $185.00 price objective on the stock. TD Cowen reaffirmed a “buy” rating on shares of Guardant Health in a research report on Thursday, May 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a research note on Tuesday, April 21st. Evercore upgraded shares of Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 price objective for the company in a research note on Tuesday, June 2nd. Finally, Barclays lifted their target price on Guardant Health from $120.00 to $150.00 and gave the company an “overweight” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $142.19.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.